EDAP TMS S.A. (EDAP) Highlights Recent UK NICE Positive Guidance for Focal Therapy Using HIFU to Treat Localized Prostate Cancer  
6/7/2012 9:19:01 AM

LYON, France, June 7, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced that the National Institute for Health and Clinical Excellence (NICE), an independent organization that advises the National Health Service (NHS) of the United Kingdom on treatment and care, recently published guidance regarding focal therapy using High Intensity Focused Ultrasound (HIFU) to treat localized prostate cancer.